(Q37235533)

19 August 2017

1 reference

title

Liver disease in injection drug users with hepatitis C, with and without HIV coinfection (English)

1 reference

19 August 2017

1 reference

1 reference

Alexander Monto

1

1 reference

19 August 2017

Sue Currie

series ordinal

2

1 reference

19 August 2017

Teresa L Wright

series ordinal

3

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Journal of Addictive Diseases

19 August 2017

published in

1 reference

19 August 2017

volume

27

1 reference

19 August 2017

issue

2

1 reference

19 August 2017

page(s)

49-59

1 reference

A 33-year follow-up of narcotics addicts

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

The long-term pathological evolution of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Risks of a range of alcohol intake on hepatitis C-related fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

The clinical spectrum of hepatitis C virus in HIV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Hyperlactataemia syndromes associated with HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1300%2FJ069V27N02_06

21 January 2018

Identifiers

DOI

10.1300/J069V27N02_06

1 reference

19 August 2017

1 reference